Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon to Test Compounds with Nuevolution's Chematics

NEW YORK (GenomeWeb News) – Lexicon Pharmaceuticals said today it will use Nuevolution’s technology to identify small molecule lead compounds against a range of highly validated drug targets.
 
Under the agreement, Lexicon will pay Nuevolution an upfront payment and would also pay milestone payments and royalties on compounds that are identified using the Nuevolution Chemetics technology if candidate molecules advance through preclinical and clinical development and onto the market.
 
Copenhagen, Denmark-based Nuevolution also will have a future option to expand its involvement through a cost and profit sharing arrangement.
 
Lexicon specifically will use Nuevolution’s Chemetics platform to screen multiple fragment-based small molecule libraries. The validated targets were identified using Lexicon’s Genome5000 program, which the company used to explore physiological and behavioral function for nearly 5,000 genes by studying corresponding genes in knockout mice.
 
Nuevolution uses DNA labeling as part of its Chematics fragment-based drug screening platform, which helps identifty potent drug leads of higher quality and more quickly than other high-throughout screening approaches, according to the company.
 

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.